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Rheumatoid Factor as a Potentiator of
Anti–Citrullinated Protein Antibody–Mediated
Inflammation in Rheumatoid Arthritis
Jeremy Sokolove,1 Dannette S. Johnson,2 Lauren J. Lahey,1 Catriona A. Wagner,1
Danye Cheng,1 Geoffrey M. Thiele,3 Kaleb Michaud,3 Harlan Sayles,3 Andreas M. Reimold,4
Liron Caplan,5 Grant W. Cannon,6 Gail Kerr,7 Ted R. Mikuls,3 and William H. Robinson1
Objective. The co-occurrence of rheumatoid factor
(RF) and anti–citrullinated protein antibody (ACPA)
positivity in rheumatoid arthritis (RA) is well described.
However, the mechanisms underlying the potential in-
teraction between these 2 distinct autoantibodies have
not been well defined. The aim of this study was to
evaluate the epidemiologic and molecular interaction of
ACPAs and RF and its association with both disease
activity and measures of RA-associated inflammation.
Methods. In a cohort of 1,488 US veterans with
RA, measures of disease activity and serum levels of
cytokines and multiplex ACPAs were compared between
the following groups of patients: double-negative (anti–
cyclic citrullinated peptide [anti-CCP]/RF), anti-
CCP/RF, anti-CCP/RF, or double-positive (anti-
CCP/RF). Additional studies were performed using
an in vitro immune complex (IC) stimulation assay in
which macrophages were incubated with ACPA ICs in
the presence or absence of monoclonal IgM-RF, and
tumor necrosis factor  production measured as a
readout of macrophage activation.
Results. Compared with the double-negative sub-
group (as well as each single-positive subgroup), the
double-positive subgroup exhibited higher disease activ-
ity as well as higher levels of C-reactive protein and
inflammatory cytokines (all P < 0.001). In vitro stimu-
lation of macrophages by ACPA ICs increased cytokine
production, and the addition of monoclonal IgM-RF
significantly increased macrophage tumor necrosis fac-
tor  production (P  0.003 versus ACPA ICs alone).
Conclusion. The combined presence of ACPAs
and IgM-RF mediates increased proinflammatory cyto-
kine production in vitro and is associated with increased
systemic inflammation and disease activity in RA. Our
data suggest that IgM-RF enhances the capacity of
ACPA ICs to stimulate macrophage cytokine produc-
tion, thereby providing a mechanistic link by which
RF enhances the pathogenicity of ACPA ICs in RA.
Rheumatoid arthritis (RA) is often characterized
by the presence of circulating autoantibodies. Rheuma-
toid factor (RF) was first described more than 50 years
ago (1–3) and is detectable in nearly 70% of patients
with RA, although its presence is not specific for
RA (4,5). Nevertheless, whether RF plays a role in RA
pathogenesis has remained unclear. More recently, at-
tention has been given to anti–citrullinated protein
antibodies (ACPAs). Anti–cyclic citrullinated peptide
(anti-CCP) assays are commonly used to test for
ACPAs, which are detectable in 70% of patients with
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RA and are highly specific for RA (6). In addition to
their use in diagnostic criteria, RF and ACPAs provide
important prognostic information.
Previous studies have examined the diagnostic
utility of RF and ACPAs (7,8), and multiple studies have
demonstrated that higher concentrations of both auto-
antibodies are associated with a more aggressive disease
course marked by increased disease activity and reduced
rates of remission (9–11). However, there has been little
investigation into the mechanisms by which these auto-
antibodies could interact and/or contribute to RA patho-
genesis. Although several in vitro (12–14) and in vivo
(15) studies have identified a potential role for ACPAs
in disease pathogenesis, the role of RF in RA pathogen-
esis remains elusive. In this study, we sought to investi-
gate the role of RF as a contributor to the RA inflam-
matory burden, both independently and in synergy with
ACPAs.
PATIENTS AND METHODS
Patient samples and clinical measures. Study subjects
included US veterans enrolled in the Veterans Affairs Rheu-
matoid Arthritis (VARA) registry, with sites across the US
(16). The registry has received Institutional Review Board
approval at each site, and the Stanford Institutional Review
Board approved the biomarker and in vitro analyses performed
using RA samples. All patients satisfied the 1987 American
College of Rheumatology classification criteria for RA (17)
and provided informed written consent and Health Insurance
Portability and Accountability Act authorization. The study
group comprised 1,488 veterans with RA (89% male); detailed
characteristics of the cohort are shown in Table 1. Banked
serum samples were available for a representative population
of 1,466 patients and were used for multiplex cytokine and
autoantibody analyses.
In addition to banked sera, VARA collects clinical
data including the baseline and longitudinal 28-joint Disease
Activity Score (DAS28) values (18), as well as baseline mea-
surements of ACPAs, obtained using a Diastat second-
generation CCP-2 antibody enzyme-linked immunosorbent
assay (ELISA) (positivity 5 units/ml; Axis-Shield). VARA
also collects RF (positivity 15 IU/ml) and high-sensitivity
C-reactive protein (hsCRP) test results, as determined by
nephelometry (Siemens). HsCRP concentrations were not
available at followup visits. Although VARA is a multicenter
project, standardized autoantibodies are measured at the
laboratory of a single investigator (GMT). HLA–DRB1 geno-
typing was conducted as previously described (19). Patients
were categorized as being positive or negative for HLA–DRB1
shared epitope (SE)–containing alleles and HLA–DR3 alleles.
Followup measures include tender and swollen joint
counts in 28 joints, erythrocyte sedimentation rate (ESR;
mm/hour), pain score (range 0–10), Multidimensional Health
Assessment Questionnaire (MD-HAQ) score (range 0–3) (20),
patient’s and provider’s global assessments (range 0–100), and
treatments. A comorbidity count (range 0–9) was calculated
for each patient, using administrative codes (21). Because we
were investigating the association of autoantibodies with fol-
lowup clinical parameters, patients were excluded if autoanti-
body or DAS28 data were unavailable, if only a single clinical
observation was recorded, or if the total followup duration was
6 months.
Multiplex cytokine analysis. Multiplex analysis of cy-
tokines and chemokines in human serum was performed using
a Bio-Plex Pro Human Cytokine 17-plex Assay (Bio-Rad) run
on a Luminex 200 system according to the manufacturer’s
instructions, with the exception that a proprietary Bio-Rad
assay dilution buffer was modified to contain reagents demon-
strated to reduce the effects of heterophilic antibodies in
multiplex immunoassays, as previously described (21). Data
processing was performed by using Bio-Plex Manager 5.0
software, and analyte concentrations (picograms per milliliter)
were interpolated from standard curves.
Multiplex autoantigen arrays. Antibodies targeting
37 putative RA-associated autoantigens were measured using a
custom bead-based immunoassay on a Bio-Plex platform, as
previously described (22,23). Of the 37 antigens, 30 are citrul-
linated and 7 are native (native histone 2A, histone 2B,
apolipoprotein A-I [Apo A-I], filaggrin 48–65 peptide, vimen-
tin, fibrinogen, and Apo-AI 231–248 peptide). Briefly, serum
was diluted and mixed with spectrally distinct florescent beads
conjugated with putative RA-associated autoantigens, fol-
lowed by incubation with anti-human phycoerythrin–labeled
antibody and analysis on a Luminex 200 instrument.
In vitro ACPA immune complex (IC) stimulation
assays. ACPA IC stimulation of human macrophages was
performed as previously described (12). Polyclonal rabbit IgG
antibodies against fibrinogen (Pierce) or human IgG derived
from patients with ACPA-positive RA (RA lgG) was used to
generate plate-bound ICs containing citrullinated fibrinogen
ICs. RA IgG derived from 3 pooled plasma samples that were
shown by ELISA to contain high levels of anti–citrullinated
fibrinogen antibodies was purified by affinity chromatography
on protein G columns, according to the instructions of the
manufacturer (Pierce).
Monoclonal IgM-RF derived from a lymphoblastoid
cell line generated from a patient with RA (24) was a generous
gift from Drs. Michael Steinitz and Reuven Laskov (Hebrew
University, Jerusalem, Israel). IgM-RF was isolated from cell
culture supernatant by ammonium sulfate precipitation,
washed, and dialyzed against phosphate buffered saline (PBS).
The resultant product was shown to contain primarily IgM,
with no contamination by human IgG. This antibody has been
demonstrated to bind human and rabbit IgG but not IgM and,
when bound to ICs, fails to bind complement (25). Additional
monoclonal IgM antibodies with in vitro RF activity that were
isolated from patients with mixed cryoglobulinemia were gen-
erously provided by Dr. Mariana Newkirk (McGill University,
Montreal, Quebec, Canada).
The purified RA IgG and monoclonal RF were sepa-
rately concentrated by centrifugation over a 100-kd molecular
weight filter column with buffer exchange to PBS (Amicon
Ultra; Millipore) and were depleted of endotoxin by filtration
through a polymyxin B column (Detoxi-Gel; Pierce). RA IgG
and IgM-RF concentrations were estimated according to op-
tical density at 280 nm, aliquoted, and stored at 80°C. For
generation of citrullinated fibrinogen ICs, flat-bottomed
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96-well culture plates were coated overnight at 4°C with 50 l
of citrullinated fibrinogen (20 g/ml), washed in PBS contain-
ing 0.05% Tween 20, and incubated for 2 hours at 4°C with
100 l of polyclonal rabbit antibodies against fibrinogen
(50 g/ml), 100 l of anti–citrullinated fibrinogen–positive IgG
(10 mg/ml), or 100 l of anti–citrullinated fibrinogen–positive
IgG preincubated with monoclonal IgM-RF (stock concentra-
tion 5 mg/ml used at 1:20 or 1:100 dilution); PBS alone was
used as a control. Wells were again washed in PBS containing
0.05% Tween 20, and macrophages (50,000/well) in 200 l of
RPMI containing 5% fetal calf serum were then added to the
wells and incubated for 16 hours, at which time levels of tumor
necrosis factor  (TNF) in culture supernatant were mea-
sured by ELISA (PeproTech). All in vitro cell stimulations
were performed in triplicate and in at least 2 separate exper-
iments. Levels of TNF production from in vitro macrophage-
stimulation assays were compared using Student’s unpaired
t-test.
Statistical analysis. Patients were categorized into the
following groups: double-negative (anti-CCP/RF; n 
206), anti-CCP/RF (n  102), anti-CCP/RF (n  134),
and double-positive (anti-CCP/RF; n  1,046). Compari-
sons of patient characteristics were examined according to
autoantibody subgroup, using chi-square tests or analysis of
variance (ANOVA). Unadjusted comparisons of the 8 contin-
uous disease activity measures assessed at enrollment were
examined using one-way ANOVA with Tukey’s post hoc test to
compare each of the 4 subgroups. Levels of each cytokine as
well as hsCRP were compared between the double-negative,
anti-CCP/RF, anti-CCP/RF, and double-positive sub-
groups, using the Kruskal-Wallis test with Dunn’s post hoc test.
The ESR was log-transformed prior to analysis to render a
more normal distribution. Given the skewed distributions, joint
counts were dichotomized into 0 tender/swollen joints and
1 tender/swollen joints, with comparisons examining the
probability of having a joint count of 0. Continuous joint
counts were reported for descriptive purposes.
We examined whether the associations observed be-
tween autoantibody status and disease activity at enrollment
were independent of other covariates, and whether these
associations were apparent over an extended period of obser-
vation. For multivariable analyses, double-negative cases
served as the referent population. Generalized linear mixed
models were used to evaluate multivariable associations of
autoantibody group with disease activity assessed during fol-
lowup. The generalized linear mixed models adjusted for the
random effects from sites and correlations between the out-
comes from the same patient over time via a compound
symmetry correlation structure. Analyses were completed us-
ing Stata version 12, SAS version 9.3, and GraphPad Prism
version 5.
Additional comparisons were performed on multiplex
cytokines as well as multiplex ACPAs, using SAM (Signifi-
cance Analysis of Microarrays) version 3.08 (24). Output was
sorted based on false discovery rates (FDRs) in order to
identify the antigens with the greatest differences in autoanti-
body reactivity between serologic subgroups. The use of FDRs
obviates the need to adjust for multiple comparisons. Hierar-
chical clustering was performed using Cluster 3.0 to arrange
the SAM results according to similarities among autoantibody
specificities, and the results were displayed using Java Tree-
View (version 1.1.3).
Table 1. Characteristics of the patients with RA at the time of study enrollment*
Characteristic
Concordant
seronegative
(n  206)
Anti-CCP/RF
(n  102)
Anti-CCP/RF
(n  134)
Concordant
seropositive
(n  1,046)
Sociodemographics and comorbidity
Age, mean  SD years 64.5 12.2 61.2  11.9 63.3  11.9 63.0  11.2
Male sex 89.3 88.2 91.8 91.1
Race/ethnicity
White 79.6 75.5 76.9 76.7
African American 15.1 16.7 15.7 16.7
Other 5.3 7.8 7.7 6.6
High school education or higher 86.7 86.7 85.6 84.0
Comorbidity count, mean  SD 2.6 1.6 2.2  1.5 2.4  1.5 2.3  1.6
RA factors
Ever smoking† 73.2 73.4 73.9 82.7
HLA–DRB1 SE positive† 54.6 77.8 54.4 76.5
2 HLA–DRB1 alleles 8.7 23.2 6.5 24.7
HLA–DR3† 25.6 14.1 32.6 12.8
Age at diagnosis, mean  SD years† 55.9 15.0 50.7  13.7 53.8 13.7 51.8  13.6
Disease duration, mean  SD years‡ 8.7 10.1 10.5  10.7 9.5  10.7 11.2  11.4
Prednisone treatment 35.0 40.7 40.7 45.2
Methotrexate treatment‡ 45.4 64.8 51.2 49.7
Biologic agent treatment 16.9 24.2 23.6 21.1
Nodules† 12.1 24.5 26.1 33.8
* Except where indicated otherwise, values are the percent. RA  rheumatoid arthritis; anti-CCP  anti–cyclic
citrullinated peptide; RF  rheumatoid factor; SE  shared epitope.
† Overall P  0.001, by analysis of variance.
‡ Overall P  0.01, by analysis of variance.
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RESULTS
ACPAs and RF in the VARA cohort. The charac-
teristics of the 1,488 patients are shown in Table 1. The
mean  SD followup was 3.6  2.8 years, with 16,822
encounters and 5,284 patient-years of observation. A
majority of the patients (90%) were male, with a mean
age of 63 years. Most of the patients (70%) were
anti-CCP/RF, 14% were anti-CCP/RF, 9% were
anti-CCP/RF, and 6.9% were anti-CCP/RF.
There were significant differences across the autoanti-
body groups for age at diagnosis, disease duration,
methotrexate treatment, and presence of nodules. Com-
pared with the other patients, those who were anti-
CCP/RF were older at the time of diagnosis, had a
shorter disease duration, were less likely to be receiving
methotrexate, and had a lower prevalence of nodules.
Ever smoking was more common among anti-
CCP/RF patients (83%) compared with patients in
the other subgroups (73–74%; P  0.001). HLA–DRB1
SE positivity was higher in groups characterized by
anti-CCP positivity (P  0.001), irrespective of RF
status. HLA–DR3 positivity was less common among
patients positive for anti-CCP antibodies (P 0.001 across
groups). The average anti–CCP-2 titer was nearly identical
in the CCP/RF and CCP/RF groups (275.85 AU
versus 273.64 AU), and similarly, the average RF titer in
the CCP/RF group was nearly identical to that in the
CCP/RF group (329.03 IU versus 328.12 IU).
Relationship between the concurrent presence of
ACPAs and RF and increased RA disease activity. The
double-positive group exhibited significantly higher
levels of RA disease activity, with a mean SD baseline
DAS28 of 4.2  1.6 compared with 3.7  1.6 in the
double-negative group, 3.4 1.6 in the anti-CCP/RF
group, and 3.9  1.7 in the anti-CCP/RF group
(overall P  0.001, by ANOVA) (Table 2). After
adjusting for multiple comparisons across the 4 groups,
the ESR, and hsCRP and DAS28 values at the time of
enrollment were higher in the double-positive group
compared with the other groups. Post-test comparisons
between each pair of groups demonstrated significantly
higher ESRs and CRP levels among the double-positive
group compared with the double-negative, anti-CCP/
RF, and anti-CCP/RF groups, and the DAS28 was
significantly higher in the double-positive group com-
pared with the double-negative and anti-CCP/RF
subgroups, with a nonsignificant trend compared with
the anti-CCP/RF subgroup.
Similarly, in multivariable models, concurrent
anti-CCP–positive and RF-positive autoantibody status
was associated with longitudinal clinical and laboratory
measures of disease activity, including the swollen joint
count, ESR, and DAS28 when compared with the
double-negative or anti-CCP/RF subgroups, while
only a similar trend was noted when compared with the
anti-CCP/RF subgroup (Table 3).
Concurrent presence of ACPAs and RF is predic-
tive of RA-associated inflammation. Compared with the
double-negative group, the double-positive group exhib-
ited significantly higher ESRs and hsCRP levels as well
as higher levels of multiple circulating inflammatory
cytokines, including TNF, interleukin-1 (IL-1), IL-6,
Table 2. Measures of disease activity in patients with rheumatoid arthritis at the time of study enrollment, according to autoantibody status*
Measure
Concordant
seronegative
(n  206)
Anti-CCP/RF
(n  102)
Anti-CCP/RF
(n  134)
Concordant
seropositive
(n  1,046)
Pain score (range 0–10) 5.1 2.8 4.3  2.7 4.8 2.7 4.8  2.8
MD-HAQ (range 0–3) 0.94 0.63 0.81  0.62 0.96 0.58 0.98  0.60
Tender 28 joint count 6.0 7.5 4.5 7.0 5.5 6.7 6.3  7.3
Swollen 28 joint count 4.1 5.4 4.0  5.7 5.3 6.6 5.8  6.4
Patient’s global assessment (range 0–100) 45.1 27.0 35.8  23.2 43.4 26.1 43.8  25.8
Provider’s global assessment (range 0–10) 39.9 24.5 29.1  19.8 32.0 25.2 37.8  23.3
Log-transformed ESR, mm/hour† 19.4 19.6 21.2 21.9 24.8 24.7 30.2  24.0
CRP, mg/liter‡ 0.92 1.78 0.92  0.74 1.20 1.78 1.36  2.13
DAS28§ 3.7 1.6 3.4  1.6 3.9 1.7 4.2  1.6
* Joint counts were dichotomized as 0 versus 1. Statistical significance, as determined by analysis of variance, was defined as P  0.00625. Values
are the mean  SD. Anti-CCP  anti–cyclic citrullinated peptide; RF  rheumatoid factor; MD-HAQ  Multidimensional Health Assessment
Questionnaire; ESR  erythrocyte sedimentation rate; CRP  C-reactive protein; DAS28  Disease Activity Score in 28 joints.
† P  0.001, overall and concordant seropositive versus concordant seronegative; P  0.007, concordant seropositive versus anti-CCP/RF; P 
0.001, concordant seropositive versus anti-CCP/RF.
‡ P  0.001, overall, concordant seropositive versus concordant seronegative and versus anti-CCP/RF; P  0.01, concordant seropositive versus
anti-CCP/RF.
§ P  0.001 overall; P  0.001, concordant seropositive versus concordant seronegative and versus anti-CCP/RF.
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IL-12p70, and IL-17A (Figure 1) (all P  0.001 by
ANOVA). Although it is likely that many cytokines,
including those most up-regulated in the double-positive
group, are highly related and thus not subject to a high
risk of Type I error in multiplex cytokine analysis,
stringent implementation of Bonferroni’s correction for
17 potentially independent cytokines would require a
P value of 0.0029 for significance, and this was achieved
for all of the cytokines shown in Figure 1.
Additionally, all cytokine levels were compared
between the double-negative group, the anti-CCP/
RF group, and a set of double-positive patients
Table 3. Multivariable associations of autoantibody status with measures of disease activity in patients with RA during followup*
Discordant
Anti-CCP/RF Anti-CCP/RF Concordant, anti-CCP/RF
Variable  coefficient P  coefficient P  coefficient P
Pain score (range 010) 0.489 0.094 0.008 0.972 0.288 0.097
MD-HAQ (range 03) 0.161 0.034 0.000 0.996 0.015 0.725
Tender joint count (0 vs. 0) 0.251 0.181 0.326 0.042 0.052 0.624
Swollen joint count (0 vs. 0)† 0.100 0.562 0.619 0.001 0.507 0.001
Patient’s global assessment (range 0100 mm) 6.088 0.015 0.212 0.925 1.588 0.315
Provider’s global assessment (range 0100 mm) 3.804 0.069 2.597 0.191 2.418 0.069
Log-transformed ESR, mm/hour‡ 0.444 0.001 0.410 0.001 0.652 0.001
DAS28§ 0.003 0.987 0.387 0.005 0.418 0.001
* The models were adjusted for age, sex, disease duration, comorbidity score, race/ethnicity, and treatment, including methotrexate, prednisone, and
biologic agents. The concordant seronegative group served as the referent population. RA  rheumatoid arthritis; anti-CCP  anti–cyclic
citrullinated peptide; RF rheumatoid factor; MD-HAQMultidimensional Health Assessment Questionnaire; ESR erythrocyte sedimentation
rate; DAS28  Disease Activity Score in 28 joints.
† P  0.426, anti-CCP/RF versus anti-CCP/RF; P  0.008, anti-CCP/RF versus anti-CCP/RF.
‡ P  0.005, concordant seropositive versus anti-CCP/RF; P  0.036, concordant seropositive versus anti-CCP/RF.
§ P  0.786, concordant seropositive versus anti-CCP/RF; P  0.002, concordant seropositive versus anti-CCP/RF.
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Figure 1. Higher serum levels of rheumatoid arthritis (RA)–associated cytokines in RA patients who were double-positive for anti–cyclic
citrullinated peptide (anti-CCP) and rheumatoid factor (RF). Patients were categorized as being double-negative (anti-CCP/RF; n  204),
anti-CCP/RF (n  96), anti-CCP/RF (n  135), or double-positive (anti-CCP/RF; n  1,031). Between-group comparisons were
performed using the Kruskal-Wallis test with Tukey’s multiple comparison post hoc test.   P  0.01;   P  0.001 versus anti-CCP/RF.
TNF  tumor necrosis factor ; NS  not significant; IL-1  interleukin-1; M-CSF  macrophage colony-stimulating factor.
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matched for age, sex, and disease duration. Three-way
group comparisons were performed using SAM version
3.08 (23), and output was sorted based on FDRs.
Notably, the use of FDRs obviates the need to adjust for
multiple comparisons. Supplementary Figure 1 (avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38307/abstract)
demonstrates significant up-regulation of 10 of 17 cyto-
kines in the double-positive group compared with the
double-negative group and both the anti-CCP/RF
and anti-CCP/RF groups.
A smaller but, in many cases, statistically signifi-
cant elevation of cytokine levels (as well as some clinical
measures of disease activity) was noted in the anti-
CCP/RF group compared with the double-negative
and anti-CCP/RF groups. We hypothesized that
such elevations in the anti-CCP/RF group may re-
flect the presence in some patients of physiologic levels
of ACPAs not detected by or below the range of the
commercial anti–CCP-2ELISA.To support this hypothe-
sis, we used a multiplex antigen array to assess ACPA
subspecificities that might be present in the anti-CCP/
RF group. Figure 2 shows that the levels of 11 of
30 ACPAs were elevated in the anti-CCP/RF group
compared with the double-negative group. Thus, we
hypothesized that low levels of ACPAs that are not
strongly represented by the anti–CCP-2 assay may syn-
ergize with RF to induce RA-associated inflammation.
Augmentation of the stimulatory capacity of
ACPA ICs by monoclonal RF. We previously demon-
strated the ability of ACPA ICs to stimulate macrophage
cytokine production via costimulation of Fc receptor
and the innate immune receptor Toll-like receptor 4 (12).
To evaluate the effect of RF on ACPAs, we preincu-
bated ACPA-containing RA IgG with monoclonal
IgM-RF before formation of ACPA ICs. As previously
described, in vitro stimulation of monocyte-derived
macrophages by ACPA ICs demonstrated increased
cytokine production (P  0.002 versus citrullinated
fibrinogen only), and the addition of monoclonal
IgM-RF resulted in a further significant increase in
macrophage TNF production as compared with ACPA
ICs alone (P  0.003) (Figure 3A). Notably, we addi-
tionally tested 2 monoclonal IgM antibodies with in vitro
RF activity, which were isolated from patients with
mixed cryoglobulinemia. However, the addition of these
IgM antibodies at 20 g/ml, 100 g/ml, and 200 g/ml
failed to augment macrophage TNF secretion in re-
sponse to ACPA ICs (data not shown).
Given the potential inclusion of IgG-RF (or
IgM-RF) in our ACPA-positive IgG preparation, we
further investigated the ability of monoclonal IgM-RF to
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 H2B/A 62-81 Cit Cyclic 
 Vimentin Cit 
 H2A/a-2 1-20 Cit
 H2A/a 1-20 Cit sm2 Cyclic 
 Enolase 1A 5-21 Cit  
 Clusterin 221-240 Cit Cyclic 
 Vim 58-77 Cit3 Cyclic sm1
 Clusterin 231-250 Cit sm1 cyclic 
 ApoE 277-296 Cit2 sm2 cyclic
 Fil 48-65 Cit Cyclic
 Fil 48-65 Cit2 V1 Cyclic
 H2B Cit
 H2A Cit
 CCP 
 Biglycan 247-266 Cit sm1 cyclic
 FibA 556-575 Cit smCyclic
 FibA 616-635 Cit3 smCyclic 
CCP+, RF+CCP-, RF- CCP-, RF+
 1/2 x 
 1/4 x
 Average 
 2 x 
 4 x 
q < 0.1%
Figure 2. Heatmap showing elevated levels of anti–citrullinated protein antibodies in the anti-CCP/RF group compared with the double-
negative group. Levels of autoantibodies against 37 putative targets of the RA immune response were compared between the anti-CCP/RF group
(n  96) and the anti-CCP/RF group (n  135) using a multiplex antigen microarray. SAM software was used to sort output based on false
discovery rates in order to identify antigens with the greatest differences in autoantibody reactivity between serologic subgroups. Labels on the color
key are the fluorescence intensity relative to the average values in the evaluated cohort. Cit citrullinated; Vim vimentin; ApoE apolipoprotein
E; Fil  filaggrin; FibA  fibrinogen A (see Figure 1 for other definitions).
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enhance the stimulatory activity of anti–citrullinated
fibrinogen ICs, this time formed with a polyclonal rabbit
antibody against fibrinogen previously demonstrated to
bind native and citrullinated fibrinogen (12) and which
could be targeted by our monoclonal IgM-RF by ELISA
and Western blotting (data not shown). In results anal-
ogous to those of previous studies, we observed the
ability of anti–citrullinated fibrinogen ICs to stimulate
macrophage cytokine production and, as with human
RA–derived IgG preparations, the ability of monoclonal
IgM-RF to augment anti–citrullinated fibrinogen IC–
induced macrophage activation, as evidenced by in-
creased cytokine production (Figure 3B).
DISCUSSION
Although several previous studies have demon-
strated increased disease activity in the presence of
either anti-CCP or RF, to our knowledge, this study is
the first to identify a synergistic role for ACPAs and RF
in mediating RA-associated inflammation and disease
activity. We demonstrated that baseline autoantibody
status was associated with select measures of disease
activity, both at presentation and over time. Specifically,
joint swelling and higher baseline DAS28 values were
more commonly observed in patients with RA who were
positive for both anti-CCP and RF and, to a lesser extent
in those positive for RF regardless of anti-CCP status.
Interestingly, ESRs were similarly increased in all
autoantibody-positive groups (both double-positive and
single-positive) compared with seronegative patients,
even after accounting for the numerically higher fre-
quency of RA-related treatments used in seropositive
cases; however, values were further increased in the
double-positive group compared with each single-
positive group. The observed increases in disease activity
and the levels of clinical markers of inflammation were
paralleled by a nearly identical pattern of elevation
among several inflammatory cytokines previously asso-
ciated with RA pathophysiology (26), including those
that we and other investigators have previously demon-
strated to be produced in response to macrophage
stimulation by ACPA ICs (12,13).
The increased inflammation and disease activity
observed in the double-positive group is supportive of a
potential role for these RA-associated autoantibodies in
mediating the pathogenesis of RA. However, because
association does not prove causality, we used an in vitro
model of ACPA IC–mediated inflammation to identify a
novel mechanism by which the interaction of ACPAs
and RF may contribute to the pathophysiology of RA
inflammation and disease activity. We thus demonstrate
a unifying mechanism by which the 2 overtly distinct
autoantibody types that characterize RA can interact to
promote RA disease pathogenesis.
RF was first identified by the ability of RA serum
to agglutinate IgG-coated sheep red blood cells, was
subsequently defined as an immunoglobulin targeting
the Fc portion of IgG (3), and is now considered to be
characteristic of the presence of RA and has been
associated with increased disease severity (9,11). How-
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Figure 3. IgM-RF augments macrophage activation by anti–
citrullinated protein antibody (ACPA) immune complexes (ICs) in
vitro. Monocyte-derived macrophages were added to plates precoated
with human citrullinated fibrinogen (cFb) ICs (A) or with citrullinated
fibrinogen ICs formed using polyclonal rabbit IgG antibodies against
fibrinogen (B), in the presence or absence of monoclonal IgM-RF.
Macrophage stimulation was assessed by measuring the level of TNF
in harvested cell culture supernatants. Results are representative of
experiments performed at least twice. Bars show the mean  SEM of
triplicate cultures. See Figure 1 for other definitions.
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ever, the pathogenic role of RF has been questioned
and, to date, poorly defined. In 1961, Ragan stated that
“the significance of rheumatoid factor in the pathogen-
esis of rheumatoid arthritis remains conjectural” (3).
More than 50 years later, little progress has been
made in our understanding. Previous studies have sug-
gested the ability of RF to accelerate experimental
models of IC-mediated vascular damage (27), and al-
though there is evidence for the ability of RF to fix
complement (28,29), other studies suggest that RF may
in fact prevent complement activation by IgG ICs, thus
leading to the speculation that the effects of RF are in
fact mediated by attachment to the Fc region of the IgG
molecule rather than complement activation (30). As
such, this study is the first to suggest a mechanistic role
of RF in RA disease propagation. Additionally, it has
long been known that RF is present in the setting of
non-RA immune activation, including most notably,
viral and bacterial infection.
Prior studies have identified the ability of RF-
expressing B cells to recognize ICs (but not monomeric
IgG) and to present the retained antigen to T cells (31),
thus enhancing the immune response to foreign antigen.
Therefore, the generation of RF may have a teleological
purpose in its potential ability to stabilize protective ICs.
We propose that soluble RF may have developed to
provide a protective evolutionary advantage against
infectious pathogens. Because the immune response
associated with RA and similar autoimmune conditions
is also associated with the presence of RF, we hypothe-
size that inflammatory disease pathogenesis has co-
opted the beneficial role of IC stabilization, thus en-
hancing the pathogenic capacity of disease-associated
autoantibodies and resultant ICs.
The current study has several limitations. Given
the large proportion of older patients examined (who
are reflective of current VA beneficiaries), caution
should be used before applying these results to a broader
RA patient population. Also, given reports highlighting
the pathogenic role that ACPAs might play in propagat-
ing RA-related joint damage (14), further analyses ex-
amining the relationship of autoantibody status with
clinical and radiographic outcomes in RA are important.
Despite use of methods optimized to minimize
the effects of heterophilic antibodies, our laboratory
studies do not eliminate the potential of heterophilic
antibodies such as RF to induce erroneously elevated
signal in sandwich immunoassays (32,33). Thus, the risk
remains that the observed elevation of cytokine levels in
the double-positive group is in part a result of such bias.
However, the relative lack of signal in the RF single-
positive group, as well as supporting clinical and ESR
data, provide evidence against a significant contribution
of such confounding in this study. Finally, the complexity
and heterogeneity of IgM-RF remain great. Although
most monoclonal RF characterized to date target the
C2–C3 interface in the Fc region on the IgG molecule
(34), the variations in exact binding sites as well as the
role of various posttranslational modifications (35,36) to
affect RF binding, as well as the typically polyclonal
nature of RF in vivo, may limit the generalizability
of our IC data generated with a single monoclonal
IgM-RF.
In summary, our results showed that a signifi-
cantly increased level of disease activity as well as
increased levels of systemic inflammation markers were
associated with the concordant presence of RF and
ACPAs in a multivariable analysis accounting for a
variety of other potentially associated clinical variables.
Here, we demonstrate a mechanism by which the IgM-
RF–ACPA interaction may directly contribute to RA
disease pathogenesis. These results not only provide
useful information for predicting the severity of RA but
also, by identifying a mechanistic interaction between
ACPAs and IgM-RF, advance our understanding of the
role of RA-associated autoantibodies in mediating the
pathogenesis of RA.
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